Glucagon like peptide 1 receptor agonists : a therapy for diabetes management
ABSTRACT: Introduction: Glucagon-like peptide 1 agonists inhibit glucose-dependent glucagon secretion, decrease gastric emptying and appetite through neural mechanisms, contribute to glucose regulation and show reduction in gly cated hemoglobin A. Methods: A bibliographic search was made on Medline®...
- Autores:
-
Rojas Henao, Natalia Andrea
Granados Vega, Elkyn Johan
- Tipo de recurso:
- Review article
- Fecha de publicación:
- 2018
- Institución:
- Universidad de Antioquia
- Repositorio:
- Repositorio UdeA
- Idioma:
- eng
- OAI Identifier:
- oai:bibliotecadigital.udea.edu.co:10495/23997
- Acceso en línea:
- http://hdl.handle.net/10495/23997
- Palabra clave:
- Diabetes Mellitus Tipo 2
Diabetes Mellitus, Type 2
Hipoglucemia
Hypoglycemia
Péptido 1 Similar al Glucagón
Glucagon-Like Peptide 1
Hemoglobina A
Hemoglobin A
- Rights
- openAccess
- License
- http://creativecommons.org/licenses/by-nc-nd/2.5/co/
| id |
UDEA2_e7f137fc661fff8516e36a1fb2eb2455 |
|---|---|
| oai_identifier_str |
oai:bibliotecadigital.udea.edu.co:10495/23997 |
| network_acronym_str |
UDEA2 |
| network_name_str |
Repositorio UdeA |
| repository_id_str |
|
| dc.title.spa.fl_str_mv |
Glucagon like peptide 1 receptor agonists : a therapy for diabetes management |
| dc.title.translated.spa.fl_str_mv |
Agonistas del receptor péptido 1 similar al glucagón : una terapia para el control de la diabetes |
| title |
Glucagon like peptide 1 receptor agonists : a therapy for diabetes management |
| spellingShingle |
Glucagon like peptide 1 receptor agonists : a therapy for diabetes management Diabetes Mellitus Tipo 2 Diabetes Mellitus, Type 2 Hipoglucemia Hypoglycemia Péptido 1 Similar al Glucagón Glucagon-Like Peptide 1 Hemoglobina A Hemoglobin A |
| title_short |
Glucagon like peptide 1 receptor agonists : a therapy for diabetes management |
| title_full |
Glucagon like peptide 1 receptor agonists : a therapy for diabetes management |
| title_fullStr |
Glucagon like peptide 1 receptor agonists : a therapy for diabetes management |
| title_full_unstemmed |
Glucagon like peptide 1 receptor agonists : a therapy for diabetes management |
| title_sort |
Glucagon like peptide 1 receptor agonists : a therapy for diabetes management |
| dc.creator.fl_str_mv |
Rojas Henao, Natalia Andrea Granados Vega, Elkyn Johan |
| dc.contributor.author.none.fl_str_mv |
Rojas Henao, Natalia Andrea Granados Vega, Elkyn Johan |
| dc.contributor.researchgroup.spa.fl_str_mv |
Promoción y Prevención Farmacéutica |
| dc.subject.decs.none.fl_str_mv |
Diabetes Mellitus Tipo 2 Diabetes Mellitus, Type 2 Hipoglucemia Hypoglycemia Péptido 1 Similar al Glucagón Glucagon-Like Peptide 1 Hemoglobina A Hemoglobin A |
| topic |
Diabetes Mellitus Tipo 2 Diabetes Mellitus, Type 2 Hipoglucemia Hypoglycemia Péptido 1 Similar al Glucagón Glucagon-Like Peptide 1 Hemoglobina A Hemoglobin A |
| description |
ABSTRACT: Introduction: Glucagon-like peptide 1 agonists inhibit glucose-dependent glucagon secretion, decrease gastric emptying and appetite through neural mechanisms, contribute to glucose regulation and show reduction in gly cated hemoglobin A. Methods: A bibliographic search was made on Medline® about pharmacology of the agonist glucagon-like peptide-1 receptor , Liraglutide, Lixisenatide, Albiglutide, Exenatide, Exenatide with long-acting release. Results: The GLP1 receptor agonist are agents involved with gly cemic balance, weight loss induction and are associated with lower risk of hypoglycemia. They have shown efficacy in the treatment of hypoglycemia in patients with type-2 diabetes. Conclusions: GLP1 receptor agonist are part of the therapies for diabetes that have shown benefits in metabolic con trol, effectiveness in weight reduction and changes in glycated hemoglobin. More studies are needed to evaluate its long-term safety |
| publishDate |
2018 |
| dc.date.issued.none.fl_str_mv |
2018 |
| dc.date.accessioned.none.fl_str_mv |
2021-11-11T21:50:06Z |
| dc.date.available.none.fl_str_mv |
2021-11-11T21:50:06Z |
| dc.type.spa.fl_str_mv |
Artículo de revisión |
| dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_dcae04bc |
| dc.type.redcol.spa.fl_str_mv |
https://purl.org/redcol/resource_type/ARTREV |
| dc.type.coarversion.spa.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.driver.spa.fl_str_mv |
info:eu-repo/semantics/article |
| dc.type.version.spa.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| format |
http://purl.org/coar/resource_type/c_dcae04bc |
| status_str |
publishedVersion |
| dc.identifier.issn.none.fl_str_mv |
0120-8705 |
| dc.identifier.uri.none.fl_str_mv |
http://hdl.handle.net/10495/23997 |
| dc.identifier.doi.none.fl_str_mv |
10.21615/cesmedicina.32.1.3 |
| dc.identifier.eissn.none.fl_str_mv |
2215-9177 |
| identifier_str_mv |
0120-8705 10.21615/cesmedicina.32.1.3 2215-9177 |
| url |
http://hdl.handle.net/10495/23997 |
| dc.language.iso.spa.fl_str_mv |
eng |
| language |
eng |
| dc.relation.ispartofjournalabbrev.spa.fl_str_mv |
CES med. |
| dc.relation.citationendpage.spa.fl_str_mv |
30 |
| dc.relation.citationissue.spa.fl_str_mv |
1 |
| dc.relation.citationstartpage.spa.fl_str_mv |
23 |
| dc.relation.citationvolume.spa.fl_str_mv |
32 |
| dc.relation.ispartofjournal.spa.fl_str_mv |
Ces Medicina |
| dc.rights.uri.*.fl_str_mv |
http://creativecommons.org/licenses/by-nc-nd/2.5/co/ |
| dc.rights.uri.spa.fl_str_mv |
https://creativecommons.org/licenses/by-nc-nd/4.0/ |
| dc.rights.accessrights.spa.fl_str_mv |
info:eu-repo/semantics/openAccess |
| dc.rights.coar.spa.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
| rights_invalid_str_mv |
http://creativecommons.org/licenses/by-nc-nd/2.5/co/ https://creativecommons.org/licenses/by-nc-nd/4.0/ http://purl.org/coar/access_right/c_abf2 |
| eu_rights_str_mv |
openAccess |
| dc.format.extent.spa.fl_str_mv |
8 |
| dc.format.mimetype.spa.fl_str_mv |
application/pdf |
| dc.publisher.spa.fl_str_mv |
Universidad CES, Facultad de Medicina |
| dc.publisher.place.spa.fl_str_mv |
Medellín, Colombia |
| institution |
Universidad de Antioquia |
| bitstream.url.fl_str_mv |
https://bibliotecadigital.udea.edu.co/bitstreams/38e2d7da-7367-4a08-ba94-6790f04f495c/download https://bibliotecadigital.udea.edu.co/bitstreams/b489af5a-f00f-46be-956a-e4ae33d4b5db/download https://bibliotecadigital.udea.edu.co/bitstreams/b15ca37b-6128-4111-b5f1-5b439b5b557b/download https://bibliotecadigital.udea.edu.co/bitstreams/ff11f9ec-93c1-4049-8f13-e35a1a4d7a0e/download https://bibliotecadigital.udea.edu.co/bitstreams/8edd1091-65e3-48c9-86ed-88a3075e2448/download |
| bitstream.checksum.fl_str_mv |
b88b088d9957e670ce3b3fbe2eedbc13 8a4605be74aa9ea9d79846c1fba20a33 540ce4cc3f7b39e4467780014edaf13a ff8f91f176659da7b2e5cbb3505a0e14 e6d1d55896f48ab9ec5822aeee130c21 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Institucional de la Universidad de Antioquia |
| repository.mail.fl_str_mv |
aplicacionbibliotecadigitalbiblioteca@udea.edu.co |
| _version_ |
1851052576493010944 |
| spelling |
Rojas Henao, Natalia AndreaGranados Vega, Elkyn JohanPromoción y Prevención Farmacéutica2021-11-11T21:50:06Z2021-11-11T21:50:06Z20180120-8705http://hdl.handle.net/10495/2399710.21615/cesmedicina.32.1.32215-9177ABSTRACT: Introduction: Glucagon-like peptide 1 agonists inhibit glucose-dependent glucagon secretion, decrease gastric emptying and appetite through neural mechanisms, contribute to glucose regulation and show reduction in gly cated hemoglobin A. Methods: A bibliographic search was made on Medline® about pharmacology of the agonist glucagon-like peptide-1 receptor , Liraglutide, Lixisenatide, Albiglutide, Exenatide, Exenatide with long-acting release. Results: The GLP1 receptor agonist are agents involved with gly cemic balance, weight loss induction and are associated with lower risk of hypoglycemia. They have shown efficacy in the treatment of hypoglycemia in patients with type-2 diabetes. Conclusions: GLP1 receptor agonist are part of the therapies for diabetes that have shown benefits in metabolic con trol, effectiveness in weight reduction and changes in glycated hemoglobin. More studies are needed to evaluate its long-term safetyRESUMEN: Introducción: los agonistas del péptido 1 similar al glucagón inhiben la secreción del glucagón dependiente de glucosa, también disminuyen el vaciamiento gástrico y el apetito a través de mecanismos neurales contri buyen a la regulación de la glucosa y muestran reducción en la hemoglobina A glicada. Métodos: búsqueda bibliográfica en Medline sobre la farmacología de los agonistas del receptor del péptido 1 similar al glucagón: liraglutide, lixisenatide, albiglutide, exenatide, exenatide con liberación de acción prolongada. Resultados: los agonistas del receptor del péptido 1 similar al glucagón son agentes involucrados con el equilibrio glucémico, inducen pérdida de peso, se asocian a un menor riesgo de hipoglucemias y han mostrado eficacia en el tratamiento de la hiperglucemia en pacientes con diabetes tipo 2. Conclusiones: los agonistas del receptor del péptido 1 similar al glucagón forman parte de las terapias para la diabetes que han mostrado beneficios en el control metabólico, efectividad en la reducción de peso y cambios en la hemoglobina A glicosilada. Aún faltan estudios que evalúen su seguridad a largo plazo.COL00746618application/pdfengUniversidad CES, Facultad de MedicinaMedellín, Colombiahttp://creativecommons.org/licenses/by-nc-nd/2.5/co/https://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Glucagon like peptide 1 receptor agonists : a therapy for diabetes managementAgonistas del receptor péptido 1 similar al glucagón : una terapia para el control de la diabetesArtículo de revisiónhttp://purl.org/coar/resource_type/c_dcae04bchttp://purl.org/coar/resource_type/c_2df8fbb1https://purl.org/redcol/resource_type/ARTREVhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionDiabetes Mellitus Tipo 2Diabetes Mellitus, Type 2HipoglucemiaHypoglycemiaPéptido 1 Similar al GlucagónGlucagon-Like Peptide 1Hemoglobina AHemoglobin ACES med.3012332Ces MedicinaPublicationCC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8823https://bibliotecadigital.udea.edu.co/bitstreams/38e2d7da-7367-4a08-ba94-6790f04f495c/downloadb88b088d9957e670ce3b3fbe2eedbc13MD52falseAnonymousREADLICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://bibliotecadigital.udea.edu.co/bitstreams/b489af5a-f00f-46be-956a-e4ae33d4b5db/download8a4605be74aa9ea9d79846c1fba20a33MD53falseAnonymousREADORIGINALGranadosElkyn_2018_GlucagonLikePeptide.pdfGranadosElkyn_2018_GlucagonLikePeptide.pdfArtículo de revisiónapplication/pdf146222https://bibliotecadigital.udea.edu.co/bitstreams/b15ca37b-6128-4111-b5f1-5b439b5b557b/download540ce4cc3f7b39e4467780014edaf13aMD51trueAnonymousREADTEXTGranadosElkyn_2018_GlucagonLikePeptide.pdf.txtGranadosElkyn_2018_GlucagonLikePeptide.pdf.txtExtracted texttext/plain27375https://bibliotecadigital.udea.edu.co/bitstreams/ff11f9ec-93c1-4049-8f13-e35a1a4d7a0e/downloadff8f91f176659da7b2e5cbb3505a0e14MD54falseAnonymousREADTHUMBNAILGranadosElkyn_2018_GlucagonLikePeptide.pdf.jpgGranadosElkyn_2018_GlucagonLikePeptide.pdf.jpgGenerated Thumbnailimage/jpeg15162https://bibliotecadigital.udea.edu.co/bitstreams/8edd1091-65e3-48c9-86ed-88a3075e2448/downloade6d1d55896f48ab9ec5822aeee130c21MD55falseAnonymousREAD10495/23997oai:bibliotecadigital.udea.edu.co:10495/239972025-03-27 00:32:59.936http://creativecommons.org/licenses/by-nc-nd/2.5/co/open.accesshttps://bibliotecadigital.udea.edu.coRepositorio Institucional de la Universidad de Antioquiaaplicacionbibliotecadigitalbiblioteca@udea.edu.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 |